urotensin II Activators
Urotensin II activators are a niche category of chemical compounds that selectively enhance the biological activity of the peptide hormone urotensin II, which is encoded by the UTS2 gene. Urotensin II (UII) is a cyclic peptide that binds to the urotensin-II receptor (UT), a G protein-coupled receptor, to exert its effects, which are widespread and include contraction of smooth muscle tissues and modulation of cellular proliferation. The activators of UII work by different mechanisms, some of which may involve the stabilization of UII in its active conformation, or by potentiating the interaction between UII and its receptor. This can result in an increased affinity of UII for the UT receptor or an enhanced receptor activation post-binding. Some activators may also prolong the action of urotensin II by inhibiting the degradation or inactivation pathways that normally limit its activity. The biochemical pathways influenced by urotensin II are complex and involve a cascade of intracellular signaling events, including the activation of phospholipase C, leading to an increase in inositol triphosphate and diacylglycerol, release of calcium from intracellular stores, and the activation of protein kinase C.
The second paragraph in the description of urotensin II activators would delve deeper into the cellular mechanisms at play. Upon activation of the UT receptor, there is a subsequent activation of various downstream signaling pathways, which can include the mitogen-activated protein kinase (MAPK) pathways, along with influences on the Rho kinase pathway, which impacts cytoskeletal organization and cellular contraction. Urotensin II activators enhance these signaling processes by ensuring that urotensin II is more effectively able to exert its regulatory functions, which span across a variety of cell types and tissues. The specificity of these activators is crucial, as they do not broadly stimulate unrelated pathways, but rather, they focus on the signaling events directly or indirectly connected to UII activity. This specificity is due to their ability to interact with the peptide or its receptor in a way that augments UII's natural biological actions, leading to an amplified response to the presence of urotensin II without altering its natural production or expression levels.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Forskolin | 66575-29-9 | sc-3562 sc-3562A sc-3562B sc-3562C sc-3562D | 5 mg 50 mg 1 g 2 g 5 g | $78.00 $153.00 $740.00 $1413.00 $2091.00 | 73 | |
Forskolin activates adenylate cyclase, leading to an increase in cAMP levels. Elevated cAMP activates PKA, which can phosphorylate various proteins, potentially leading to enhanced signaling pathways that urotensin II is involved in, such as vasoconstriction and smooth muscle contraction. | ||||||
PMA | 16561-29-8 | sc-3576 sc-3576A sc-3576B sc-3576C sc-3576D | 1 mg 5 mg 10 mg 25 mg 100 mg | $41.00 $132.00 $214.00 $500.00 $948.00 | 119 | |
PMA is a potent activator of protein kinase C (PKC). Activation of PKC can lead to the phosphorylation of proteins that are part of the signaling cascade involving urotensin II, potentially leading to enhanced smooth muscle contraction. | ||||||
D-erythro-Sphingosine-1-phosphate | 26993-30-6 | sc-201383 sc-201383D sc-201383A sc-201383B sc-201383C | 1 mg 2 mg 5 mg 10 mg 25 mg | $165.00 $322.00 $570.00 $907.00 $1727.00 | 7 | |
Sphingosine-1-phosphate is a signaling lipid that can activate G protein-coupled receptors, which could enhance the signal transduction pathways that urotensin II is part of, particularly in vasoconstriction and cardiovascular effects. | ||||||
Thapsigargin | 67526-95-8 | sc-24017 sc-24017A | 1 mg 5 mg | $136.00 $446.00 | 114 | |
Thapsigargin raises intracellular calcium levels by inhibiting the sarcoplasmic/endoplasmic reticulum Ca2+ ATPase (SERCA). Increased intracellular calcium can potentiate the signaling pathways of urotensin II, which is known to be involved in smooth muscle contraction. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002 is a PI3K inhibitor, which may lead to a compensatory response increasing cellular sensitivity to other pathways, including those where urotensin II is active, potentially enhancing its signal transduction related to vasoconstriction and cardioprotective effects. | ||||||
A23187 | 52665-69-7 | sc-3591 sc-3591B sc-3591A sc-3591C | 1 mg 5 mg 10 mg 25 mg | $55.00 $131.00 $203.00 $317.00 | 23 | |
A23187 is an ionophore that increases intracellular calcium levels. The increase in calcium can activate signaling pathways where urotensin II plays a role, facilitating its effects on smooth muscle tone and cardioprotective actions. | ||||||
Caffeine | 58-08-2 | sc-202514 sc-202514A sc-202514B sc-202514C sc-202514D | 50 g 100 g 250 g 1 kg 5 kg | $33.00 $67.00 $97.00 $192.00 $775.00 | 13 | |
Caffeine inhibits phosphodiesterases, leading to increased cAMP levels, which can enhance PKA activity. This increase in PKA activity can potentiate the signaling pathways that involve urotensin II, particularly in modulating vascular tone. | ||||||
Capsaicin | 404-86-4 | sc-3577 sc-3577C sc-3577D sc-3577A | 50 mg 250 mg 500 mg 1 g | $96.00 $160.00 $240.00 $405.00 | 26 | |
Capsaicin stimulates vanilloid receptors, which can lead to increased intracellular calcium levels. This can potentially enhance the activity of urotensin II in its signaling pathways, specifically in pain sensation and cardiovascular effects. | ||||||
Isoproterenol Hydrochloride | 51-30-9 | sc-202188 sc-202188A | 100 mg 500 mg | $28.00 $38.00 | 5 | |
Isoproterenol is a beta-adrenergic agonist that increases cAMP levels in cells, which can enhance the activity of PKA. This may lead to an enhanced effect of urotensin II in its role in cardiovascular modulation and smooth muscle function. | ||||||
Histamine, free base | 51-45-6 | sc-204000 sc-204000A sc-204000B | 1 g 5 g 25 g | $94.00 $283.00 $988.00 | 7 | |
Histamine binds to its receptors and can influence intracellular signaling pathways, including those involving calcium mobilization. This could potentially enhance the signaling pathways that urotensin II is a part of, such as those affecting vascular tone and smooth muscle contraction. | ||||||